Spinraza’s sales were a bright spot in Biogen’s second-quarter earning call this month — and that’s very good news for the University of Massachusetts.
A university spokesperson could not confirm the exact amounts and Biogen (BIIB) did not respond to a request for comment. However, based on figures provided by one of the inventors, STAT estimated that the university has received about $10.5 million since the FDA approved the drug for spinal muscular atrophy in December 2016.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
